Switching is a "hot" topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient's dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biological to another.
The switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group / Ganzetti, Giulia; Campanati, Anna; Bettacchi, Alberta; Brandozzi, Giuliano; Brisigotti, Valerio; Bugatti, Leonardo; Cataldi, Ivana; Filosa, Giorgio; Giacchetti, Alfredo; Lemme, Giuseppe; Morresi, Lorenzo; Nicolini, Massimiliano; Postacchini, Valentina; Ricotti, Giuseppe; Rosa, Laura; Simonacci, Marco; Offidani, Annamaria. - In: GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA. - ISSN 1827-1820. - (2016).
The switching from a biological therapy to another biologic agent in psoriatic patients: the experience of PsOMarche group
GANZETTI, GIULIA;CAMPANATI, Anna;BRISIGOTTI, VALERIO;POSTACCHINI, VALENTINA;ROSA, LAURA;OFFIDANI, ANNAMARIA
2016-01-01
Abstract
Switching is a "hot" topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient's dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biological to another.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
